Ajooni Biotech Ltd

Ajooni Biotech demonstrates fluctuating sales performance. The compounded sales growth has been strong over the past decade. Compounded profit growth also shows a similar trend. However, the operating profit margin has fluctuated, indicating potential operational inefficiencies.

| Metric | 2017-2019 | 2020-2022 | 2023 | 2024 | 2025 | |------------------|------------|------------|--------|--------| | Compounded Sales Growth (%) | 27.67% | 8.33% | 24.33% | 43% | | Compounded Profit Growth (%) | 44.33% | 25.67% | 56% |

The capital efficiency and returns of Ajooni Biotech are relatively low. The Return on Capital Employed (ROCE) is below industry standards. This indicates that the company is not effectively utilizing its capital to generate profits. The asset turnover ratio and cash conversion cycle also suggest inefficiencies in working capital management.

Ajooni Biotech's financial health shows a mix of stability and potential concern. The company maintains a relatively low debt-to-equity ratio, suggesting controlled leverage. Interest coverage appears adequate.

The shareholding pattern of Ajooni Biotech indicates a decreasing promoter holding. The reduction in promoter stake over the years raises concerns about the alignment of management with shareholders. Institutional holding is also minimal, suggesting limited confidence from institutional investors.

Ajooni Biotech exhibits a high cash conversion cycle, indicating inefficient working capital management. The company takes a significant amount of time to convert its investments in inventory and receivables into cash. A prolonged cash conversion cycle may lead to liquidity issues and increased operational costs.

The shareholding pattern of Ajooni Biotech indicates a decreasing promoter holding. The reduction in promoter stake over the years raises concerns. A decreased promoter holding may decrease investors confidence.

Ajooni Biotech has minimal institutional holding. The lack of significant investment from FIIs and DIIs suggests limited confidence from institutional investors. Low institutional interest may impact stock liquidity and valuation.